0001193125-26-100432
SEC filingMediciNova, Inc. reported a net loss of $12.0 million for fiscal year 2025, driven by an operating loss of $13.3 million. The company generated minimal revenue of $410,000, which was offset by significant operating expenses totaling $13.7 million, primarily consisting of research, development and patents ($7.2 million) and general and administrative costs ($6.2 million). The loss was partially mitigated by interest income of $1.3 million. The company's cash position decreased by $9.6 million during the year, ending with $30.8 million in cash and cash equivalents. Total assets stood at $45.6 million, with stockholders' equity of $41.6 million. The company continues to operate with negative profitability while maintaining a research-focused business model.
MediciNova, Inc. reported a net loss of $12.0 million for fiscal year 2025, representing continued negative financial performance. The company generated minimal revenue of $410,000 while incurring substantial operating expenses totaling $13.7 million. The operating loss was $13.3 million, partially offset by interest income of $1.3 million. The company's comprehensive loss also totaled $12.0 million. No prior period comparison figures are provided in the source data for year-over-year analysis.
The company reported revenue of $410,000 for fiscal year 2025. The document does not provide segment breakdown, geographic mix, or specific growth drivers for this revenue. The cost of services associated with this revenue was $379,000. No additional revenue analysis can be performed based on the provided data as no segment or product line information is disclosed.
MediciNova operated at a significant loss during fiscal year 2025. With revenue of $410,000 and cost of services of $379,000, the company had minimal gross profit. Operating expenses totaled $13.7 million, consisting primarily of research, development and patents ($7.2 million) and general and administrative costs ($6.2 million). The company's cost structure is heavily weighted toward research and development activities, with R&D expenses representing approximately 53% of total operating expenses. No margin percentages can be calculated as the necessary data for gross margin and operating margin calculations is not fully provided.
The company used $9.8 million in cash from operating activities during fiscal year 2025, primarily due to the net loss of $12.0 million offset by non-cash adjustments including stock-based compensation of $829,000. Investing activities used $3,000 while financing activities provided $244,000 from equity issuance. The net change in cash was a decrease of $9.6 million. The balance sheet shows total assets of $45.6 million, including cash and cash equivalents of $30.8 million, goodwill of $9.6 million, and in-process research and development of $4.8 million. Total liabilities were $4.0 million, resulting in stockholders' equity of $41.6 million. The company maintains a strong cash position relative to its liabilities.
The provided document does not contain management guidance, strategic priorities, or specific risk factors that would allow for an outlook analysis. No forward-looking statements or projections are included in the extracted financial data. The company appears to be in a development stage with significant research and development expenditures and minimal revenue generation.